Aduro Biotech Appoints Oncology Expert and Industry Veteran

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer

BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO ) today announced the appointment of Natalie R. Sacks, M.D., to the position of chief medical officer.

“Dr. Sacks’ clinical background as well as her broad experience in all aspects of product development – from global clinical and regulatory strategy through reimbursement and expansion indications – will be instrumental in guiding our internal and partnered programs,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “With multiple immunotherapies from Aduro’s diverse LADD, STING and B-select technology platforms advancing into and through clinical development, it is an ideal time to welcome Natalie to our executive team.”

Prior to joining Aduro, Natalie served as an advisor on development strategy for multiple firms.  Previously, she was vice president of Clinical Development at Onyx Pharmaceuticals where she played a key role in the development and approval of Kyprolis® and in business development strategy.  Prior to that, she served as vice president of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, ranging from IND filing to late-stage development, including Cometriq ™ . Earlier in her career, she held positions of increasing responsibility at Cell Genesys, culminating as vice president of Clinical Development. Cell Genesys was focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cells.  Prior to her tenure in biotechnology, she served in a variety of research and analytical roles at academic institutions and companies including Massachusetts General Hospital, Medical College of Pennsylvania, and ICI-Stuart Pharmaceuticals.

In addition to her industry experience, Dr. Sacks holds an active faculty appointment at the University of California, San Francisco (UCSF) where she is an assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College.

“I am excited to be joining Aduro, a truly unique company in the immunotherapy field with multiple promising platforms,” said Natalie Sacks, M.D., chief medical officer of Aduro. “The immuno-oncology field is rapidly evolving toward combination regimens and having a number of approaches in our portfolio makes us a strong force in the industry. Having worked with Aduro in a consulting capacity previously, I recognize the potential of our innovative platform technologies to change the landscape of cancer treatment, and I am delighted to be a part of advancing this important work.”

About Aduro Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit  www.aduro.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended  June 30, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact: Alexandra Santos Sr. Director, Corporate Affairs 510 809 9231 Media Contact: Angela Bitting 925 202 6211 press@aduro.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 204

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 180

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 61

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 182

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 191

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Coloplast A/S Highlights Impressive Full-Year Performance

Updated Category News Views 231

Coloplast A/S Financial Results Overview Coloplast A/S recently announced its full-year financial results for the fiscal year 2023/24, highlighting a solid performance characterized by growth and resilience across various business sectors. Their latest report demonstrates a robust organic growth rate of 8%, coupled with a notable EBIT margin of 27%. In monetary terms, the...

Continue Reading
Introducing Sproutr’s Innovative Program Placement Services

Updated Category News Views 200

Sproutr Unveils Comprehensive Program Placement Services Sproutr, a leading firm in insurance program design and product development, has launched its innovative Program Placement Services. This new offering aims to streamline the entire process of insurance program development, ensuring that it aligns well from the initial design to the final placement with carriers. The...

Continue Reading
Unstoppable Domains Introduces .DEMOS: Redefining Digital Identity

Updated Category News Views 147

Introducing .DEMOS: A New Era of Digital Identity In an exciting development, Unstoppable Domains has rolled out a new top-level domain, .DEMOS, in collaboration with Kynesys.xyz. This innovative domain is positioned as a Web3-first solution designed to foster connection and collaboration in a borderless internet landscape. The name .DEMOS is derived from the Greek term...

Continue Reading
Investors Urged to Join Class Action Against Open Lending Corporation

Updated Category News Views 193

Open Lending Corporation: A Call to Action for Affected Investors Investors suffering heavy losses in Open Lending Corporation (NASDAQ: LPRO) are presented with the chance to take action. It's an opportunity for those impacted by the recent financial discrepancies and corporate disclosures to become lead plaintiffs in a class action lawsuit. Class Action Lawsuit Details...

Continue Reading
McAfee Revolutionizes Digital Security with AI Techniques

Updated Category News Views 253

Innovative Protection: McAfee Leads in AI-Powered Security Recognized as a leader in online security, McAfee has become synonymous with consumer safety in a rapidly evolving digital landscape. With the escalation of online threats, including sophisticated deepfakes and scams, McAfee's advanced artificial intelligence capabilities make it the prime choice for individuals...

Continue Reading